Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and a Waiver under 18 U.S.C. §208(b)(3)

Larry B. Goldstein, M.D.

Committee: Peripheral & Central Nervous System Drugs Advisory Committee

Meeting Date: March 7, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to Biologic License Application (BLA) 125104/15, Tysabri (Natalizumab) injection, sponsored by Biogen Idec, Inc. and Elan Pharmaceuticals, a subsidiary of Elan Corporation, plc., issues on the agenda for this meeting include (1) the risks (including progressive multifocal leukoencephalopathy (PML)) associated with Tysabri administration, (2) the efficacy of Tysabri for the treatment of patients with relapsing forms of multiple sclerosis to delay the progression of physical disability and to reduce the frequency of clinical exacerbations, (3) the possible return of Tysabri to the market place, and (4) the proposed risk management plan(s) for Tysabri, I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	**Nature**	**Magnitude**
Unrelated Consulting	Competitor	From $10,001 to $50,000 per year
Unrelated Consulting	Competitor	Less than $10,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of this interest the waiver is not valid.

//S// **2/1/06**

Signature of SGE Date